SG Americas Securities
CLSD

SG Americas Securities’s Clearside Biomedical CLSD Stock Holding History

SG Americas Securities’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,151
Closed -$49K – 2917
2024
Q1 		$49K Buy
+2,151
New +$46.4K ﹤0.01% 2771
2019
Q3 		– Sell
-1,103
Closed -$16K – 3029
2019
Q2 		$16K Sell
1,103
-2,713
-71% -$48.4K ﹤0.01% 2993
2019
Q1 		$79K Buy
3,816
+1,481
+63% +$29.4K ﹤0.01% 3109
2018
Q4 		$37K Buy
+2,335
New +$110K ﹤0.01% 2859

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

SG Americas Securities's CLSD Position: Q2 2024 in Review

SG Americas Securities sold out of Clearside Biomedical (CLSD) in Q2 2024, closing a stake of 2,151 shares — an estimated $49K sold.

SG Americas Securities first reported a position in CLSD in Q4 2018 and held it in 4 quarters. The position peaked at $79K in Q1 2019. 47 funds tracked by Wall St. Rank hold CLSD as of Q2 2024.

  • SG Americas Securities reported no remaining Clearside Biomedical position as of Q2 2024 after selling out during the quarter.
  • SG Americas Securities sold 2,151 Clearside Biomedical shares in Q2 2024, an estimated $49K.
  • SG Americas Securities first reported a position in Clearside Biomedical in Q4 2018 and held it in 4 quarters.
  • SG Americas Securities's Clearside Biomedical position peaked at $79K in Q1 2019.
  • 47 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2024.

Based on SG Americas Securities's 13F filing for Q2 2024, filed 12 Jul 2024.